 |
|
|
| |
Sofosbuvir in Combination With Pegylated Interferon-alfa and Ribavirin for 12 Weeks Provides High SVR Rates in HCV-Infected Genotype 2 or 3 Treatment-Experienced Patients With and Without Compensated Cirrhosis: Results From the LONESTAR-2 Study
|
| |
| |
Reported by Jules Levin
Asian Pacific Association for the Study of the Liver (APASL), March 12-15, 2014, Brisbane, Australia
Eric Lawitz,1 Fred F. Poordad,1 Diana M. Brainard,2 Robert H. Hyland,2 Di An,2 William T. Symonds,2 John G. McHutchison,2 Fernando E. Membreno1
1Texas Liver Institute and the University of Texas Health Science Center, San Antonio, TX; 2Gilead Sciences, Inc., Foster City, CA, USA
|
| |
|
|
|
|
|
